Bangs Laboratories

Executive Summary

Bangs Laboratories, founded in 1988 and headquartered in Fishers, Indiana, is a leading manufacturer of polymer, silica, and magnetic microspheres. These microspheres serve as critical reagents and calibrators in medical diagnostics, biopharma, and life sciences, powering applications such as nucleic acid isolation, lateral flow assays, flow cytometry, and particle sizing. With over 35 years of expertise in microsphere synthesis and fine particle analysis, the company partners with diagnostic and instrument developers to enhance assay performance and reliability. As a private entity, Bangs Laboratories benefits from stable demand driven by the growth of in vitro diagnostics and personalized medicine, positioning itself as an essential supplier in the healthcare supply chain. Its products are integral to both established and emerging technologies, including liquid biopsy and point-of-care testing, which are experiencing accelerating adoption globally. Looking ahead, Bangs Laboratories is well-positioned to capitalize on several tailwinds, including the expansion of companion diagnostics, increased use of magnetic beads for next-generation sequencing (NGS) library preparation, and the shift toward decentralized testing. The company's deep technical expertise and custom capabilities enable it to serve both large diagnostic OEMs and emerging biotech firms. While the company remains privately held, its consistent performance and strategic investments in new product development suggest a stable growth trajectory. Key upcoming catalysts include new product launches targeting NGS and liquid biopsy applications, as well as potential partnerships with major diagnostic companies seeking high-performance microspheres for next-generation assays.

Upcoming Catalysts (preview)

• Q3 2026Launch of magnetic microspheres optimized for NGS library prep70% success
• Q2 2026Partnership with a top diagnostic firm for lateral flow assay components60% success
• Q4 2026Expansion into drug delivery via strategic collaboration for targeted therapies50% success